On July 8, 2025, Jasper Therapeutics (JSPR, Financial) witnessed a significant shift in analyst ratings and target price projections. BMO Capital's analyst, Kostas Biliouris, downgraded the stock rating from "Outperform" to "Market Perform," indicating a change in the outlook for JSPR.
In addition to the downgrade in rating, BMO Capital has also revised its target price for Jasper Therapeutics. The new target price is set at $4.00, which is a substantial decrease from the previous target of $15.00. This adjustment reflects a 73.33% reduction in the projected valuation of JSPR.
The new target price and rating suggest a cautious stance on the stock's future performance in the market. Investors and stakeholders in Jasper Therapeutics (JSPR, Financial) are advised to stay informed on future developments and market conditions that may affect the stock's performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $29.13 with a high estimate of $70.00 and a low estimate of $4.00. The average target implies an upside of 853.45% from the current price of $3.05. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
